Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
regorafenib + sorafenib
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Regorafenib + sorafenib is a combination of two oral small molecule multikinase inhibitors used in the treatment of advanced cancers. Both drugs inhibit multiple protein kinases involved in tumor angiogenesis and oncogenesis. Regorafenib is approved for metastatic colorectal cancer, unresectable or metastatic gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (HCC) after prior therapy with sorafenib[1][2]. Sorafenib is approved for advanced renal cell carcinoma and HCC. The combination itself does not have a unique approval or established clinical use as a fixed regimen; rather, regorafenib is often used sequentially after progression on sorafenib in HCC[2][3]. Both agents act by inhibiting kinases such as VEGFRs and PDGFRs to block tumor growth and angiogenesis.
- Brand names
- Stivarga (regorafenib)Nexavar (sorafenib)
- Other names
- regorafenib + sorafenib
02
Targets
PDGFRB (Platelet-derived growth factor receptor beta)BRAF V600EVEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)RAF1 (c-Raf-1 (Y340D/Y341D))
Beyond the preview
Go deeper on regorafenib + sorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on regorafenib + sorafenib.